Oncologic 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: What All Physicians Need to Know

被引：3

作者：

Montilla-Soler, Jaime L. ^{[1
]}

Makanji, Rikesh J. ^{[1
]}

Barron, Bruce J. ^{[2
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiol, 12902 Magnolia Dr,RM WCB 13586, Tampa, FL 33602 USA

[2] Emory Univ Hosp, Dept Radiol, Atlanta, GA 30322 USA

来源：

AMERICAN JOURNAL OF MEDICINE | 2018年 / 131卷 / 04期

关键词：

FDG; Oncologic Imaging; Patient Preparation; PET; PET/CT; PET Imaging; BROWN ADIPOSE-TISSUE; MANAGEMENT; PET; HYPERGLYCEMIA; MALIGNANCIES;

D O I：

10.1016/j.amjmed.2017.12.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Fluorine-18 fluorodeoxyglucose (F-18-FDG) positron emission tomography (PET) hybrid examinations (PET/computed tomography, PET/magnetic resonance imaging) have become the most common PET imaging tools in the evaluation of the oncologic patient. Therefore it is of paramount importance that physicians who take care of oncology patients in any capacity are familiar with the basics of when these examinations are indicated, know how to best prepare the patients, and understand the benefits and limitations of the procedure. Additionally, it is important to understand which medical conditions and medications need to be controlled to maintain the diagnostic accuracy of these tests. In this article we aim to explain what 18F-FDG is, how to best prepare our patients, what PET is, and how these examinations are interpreted. Finally, we discuss some of the limitations of these examinations. (C) 2018 Elsevier Inc. All rights reserved.

引用

页码：357 / 364

页数：8

共 14 条

[1] ACR Guidelines and Standards Committee, ACR SPR PRACT PAR PE
[2] American College of Radiology (ACR), CANC PET REG
[3] Management of Hyperglycemia in Hospitalized Patients with Renal Insufficiency or Steroid-Induced Diabetes
Baldwin, David
Apel, Jill
[J]. CURRENT DIABETES REPORTS, 2013, 13 (01) : 114 - 120
[4] Altered Biodistribution on FDG-PET with Emphasis on Brown Fat and Insulin Effect
Cohade, Christian
[J]. SEMINARS IN NUCLEAR MEDICINE, 2010, 40 (04) : 283 - 293
[5] Dual-Time-Point FDG PET/CT for the Evaluation of Pediatric Tumors
Costantini, Danny L.
Vali, Reza
Chan, Jeffery
McQuattie, Susan
Charron, Martin
[J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2013, 200 (02) : 408 - 413
[6] Malignancies with Low Fluoro-deoxyglucose Uptake at PET/CT: Pitfalls and Prognostic Importance
Flavell, Robert R.
Naeger, David M.
Aparici, Carina Mari
Hawkins, Randall A.
Pampaloni, Miguel H.
Behr, Spencer C.
[J]. RADIOGRAPHICS, 2016, 36 (01) : 293 - 294
[7] MANAGEMENT OF HYPERGLYCEMIA IN DIABETIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES DURING DEXAMETHASONE THERAPY
Gosmanov, Aidar R.
Goorha, Salil
Stelts, Sundae
Peng, Limin
Umpierrez, Guillermo E.
[J]. ENDOCRINE PRACTICE, 2013, 19 (02) : 231 - 235
[8] Mettler F., 2012, ESSENTIALS NUCL MED, V6th ed.
[9] Shreve P, 2011, CLINICAL PET-CT IN RADIOLOGY: INTEGRATED IMAGING IN ONCOLOGY, P1, DOI 10.1007/978-0-387-48902-5
[10] Impact on Patient Management of [18F]-Fluorodeoxyglucose-Positron Emission Tomography (PET) Used for Cancer Diagnosis: Analysis of Data From the National Oncologic PET Registry
Subramaniam, Rathan M.
Shields, Anthony F.
Sachedina, Archana
Hanna, Lucy
Duan, Fenghai
Siegel, Barry A.
Hillner, Bruce E.
[J]. ONCOLOGIST, 2016, 21 (09) : 1079 - 1084

← 1 2 →